TMCnet News
DermTech Presents Two Abstracts at Fall Clinical Dermatology ConferenceDermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the presentation of two abstracts at the 36th Annual Fall Clinical Dermatology Conference in Las Vegas, Nevada. "An Adhesive Patch Biopsy Based Gene Expression Test to Noninvasively Differentiate Basal Cell and Squamous Cell Carcinomas from Actinic Keratoses and Other Skin Lesions of Similar Appearance," by James Sligh, MD, PhD, of the Southern Arizona VA Healthcare System and University of Arizona, et al, highlighted the utility of non-invasive gene expression testing in differentiating primary cutaneous BCC (News - Alert) and SCC cases from benign and precursor lesions such as AK, with high sensitivity and specificity. Results demonstrated that with a robust qRT-PCR (News - Alert) strategy utilizing a novel 13-target gene panel, BCC and SCC cases were successfully differentiated from non-cancerous skin lesions of similar clinical appearance with a sensitivity of 91% and a specificity of 87%, based on 160 non-invasively collected adhesive patch skin biopsies (p<0.001; AUC 0.95). "BCC and SCC are the most common cancers of man. Adhesive patch smpling of skin coupled with gene expression profiling represents a major step for identification of these malignancies without the need for a traditional skin biopsy," said Dr. Sligh. The second abstract, "Health Economic Implications of a Noninvasive Gene Expression Test for Primary Cutaneous Melanoma," by John Hornberger, MD, Stanford University and Darrell Rigel, MD, New York University Medical Center, investigated the cost savings and outcomes impact of the pigmented lesion assay (PLA) use versus visual inspection (VI) in patients with pigmented lesions suggestive of melanoma. The improved accuracy of the PLA versus VI led to fewer unnecessary procedures and office visits, without negative impact on the early detection of melanoma. This resulted in lower costs for initial biopsy ($211), subsequent excisions ($86), surveillance management ($77), and management of melanoma ($508) as well as improved patient care and experience. About DermTech DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. For additional information visit: dermtech.com. View source version on businesswire.com: http://www.businesswire.com/news/home/20171013005001/en/ |
